文献速递小儿麻醉

瑞马唑仑用于儿科择期手术全麻的安全性与有效性

Safety and efficacy of remimazolam tosilate for general anaesthesia in paediatric patients undergoing elective surgery: a multicentre, randomised, single-blind, controlled trial.
PubMed 文献 · Anaesthesia · 2024-11-22

本研究为多中心随机单盲对照试验,纳入3-6岁择期手术患儿187例,按3:1随机接受瑞马唑仑或丙泊酚全麻。两组麻醉维持成功率相似(99% vs 98%,率差1.4%,95%CI -2.9-5.8%,P=0.441),瑞马唑仑组不良事件发生率低于丙泊酚组(19% vs 49%)。

要点

  • 瑞马唑仑用于3-6岁患儿全麻诱导和维持,成功率与丙泊酚相当。
  • 瑞马唑仑组不良事件发生率19%,低于丙泊酚组的49%。
  • 诱导剂量瑞马唑仑0.3 mg.kg-1,维持1-3 mg.kg-1.h-1。

核心结论

  • 瑞马唑仑用于学龄前儿童全麻诱导和维持耐受良好,且不劣于丙泊酚。

研究设计与样本

  • 多中心、随机、单盲、对照试验,纳入3-6岁ASA 1或2级、BMI 14-25 kg.m-2择期全麻气管插管手术患儿。
  • 共分析187例,瑞马唑仑组140例,丙泊酚组47例,随机比例3:1。

主要发现

  • 所有患儿均成功完成麻醉诱导。
  • 麻醉维持成功率瑞马唑仑组139例(99%),丙泊酚组46例(98%),率差1.4%(95%CI -2.9-5.8%,P=0.441)。
  • 不良事件发生率瑞马唑仑组27例(19%),丙泊酚组23例(49%)。

关键数值与推荐

  • 诱导剂量:瑞马唑仑0.3 mg.kg-1或丙泊酚2.5 mg.kg-1,未达意识消失可追加一次。
  • 维持输注:瑞马唑仑1-3 mg.kg-1.h-1或丙泊酚4-12 mg.kg-1.h-1,联合瑞芬太尼0.1-0.5 μg.kg-1.min-1。
  • 所有患儿先接受芬太尼3 μg.kg-1。

临床怎么用

  • 瑞马唑仑可作为学龄前儿童择期手术全麻诱导和维持的替代选择,不良事件较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Remimazolam is an ultra-short-acting benzodiazepine sedative drug. This study aimed to compare the efficacy and safety of remimazolam with propofol for induction and maintenance of general anaesthesia in children undergoing elective surgery. METHODS: Children (aged 3-6 y, ASA physical status 1 or 2, BMI 14-25 kg.m-2) undergoing elective surgery under general anaesthesia with tracheal intubation were eligible for inclusion. Children were allocated randomly using a web-based system to receive either remimazolam or propofol in a 3:1 ratio. After receiving fentanyl 3 μg.kg-1, children received their allocated drug for both induction and maintenance of general anaesthesia. Induction doses were remimazolam 0.3 mg.kg-1 or propofol 2.5 mg.kg-1, with a second dose given should they not achieve loss of consciousness. After neuromuscular blockade and tracheal intubation, maintenance anaesthesia was achieved with an infusion either remimazolam 1-3 mg.kg-1.h-1 or propofol 4-12 mg.kg-1.h-1, alongside a remifentanil infusion (0.1-0.5 μg.kg-1.min-1) titrated to surgical stimulus and haemodynamic parameters. Primary outcomes were the incidence of successful induction and maintenance of anaesthesia. Secondary outcomes included: time to loss of consciousness, awakening and tracheal extubation; incidence of emergence delirium and moderate or severe pain in post-anaesthesia care unit; incidence of negative behaviour change after surgery at postoperative day 3; and incidence of adverse events. RESULTS: A total of 187 children were analysed (140 allocated to remimazolam and 47 to propofol). All children achieved successful induction of anaesthesia. Successful maintenance of anaesthesia was achieved in 139 (99%) children who received remimazolam compared with 46 (98%) who received propofol (rate difference 1.4%, 95%CI -2.9-5.8%, p = 0.441). Adverse events occurred in 27 (19%) children who received remimazolam and 23 (49%) who received propofol. DISCUSSION: Remimazolam was well tolerated for the induction and maintenance of general anaesthesia in pre-school-age children and was non-inferior to propofol.

来源:Anaesthesia,查看原文。版权归原作者所有。

引用

  1. Fang YB, Zhong JW, Szmuk P, et al. Safety and efficacy of remimazolam tosilate for general anaesthesia in paediatric patients undergoing elective surgery: a multicentre, randomised, single-blind, controlled trial. Anaesthesia. 2024. PMID: 39577009. doi:10.1111/anae.16475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。